

ERRATUM

Open Access



# Erratum to: miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer

Helong Zhao, Tasha Wilkie, Yadwinder Deol, Amita Sneh, Akaansha Ganju, Mustafa Basree, Mohd W. Nasser\* and Ramesh K. Ganju\*

## Erratum

After publication of [1] it came to the authors' attention that in the abstract. The sentence "In the present study, we show that S100A7 significantly downregulates the expression of miR-29b in Estrogen Receptor (ER)-positive breast cancer cells (represented by MCF7), and significantly upregulates miR-29b in ER-negative cells (represented by MDA-MB-231)". Was Incorrect, the correct statement is "In the present study, we show that S100A7 significantly upregulates the expression of miR-29b in Estrogen Receptor (ER)-positive breast cancer cells (represented by MCF7), and significantly downregulates miR-29b in ER-negative cells (represented by MDA-MB-231)".

Published online: 16 November 2015

## Reference

1. Zhao H, Wilkie T, Deol Y, Sneh A, Ganju A, Basree M, et al. miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer. *Mol Cancer*. 2015;14:11.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



\* Correspondence: Mohd.Nasser@osumc.edu; Ramesh.Ganju@osumc.edu  
Department of Pathology, The Ohio State University Wexner Medical Center,  
840 BRT, 460 W 12th Ave, Columbus 43210, OH, USA